Celexa, Citalopram News

Almost one in 10 older adults in the United States has some form of depression, and one-fifth among them contemplates suicide.

Depression in older adults too often goes unrecognized and untreated, resulting in untold misery, worsening of medical illness, and early death.

The Warren County Coroner has ruled the May 24 death of a judge a suicide. Judge James Heath died from 'multiple drug intoxication,' Coroner Russell Uptegrove said today.

Two normally healthful foods -- chicken and leafy vegetables -- were the leading causes of recent food-borne illness.

See All Articles by Author The growing prevalence of autism worldwide has parents and clinicians searching for effective treatment options.

Common medication ineffective for children with autism The medication citalopram is often prescribed for children with autism to reduce repetitive behaviors.

All drugs carry side effects. Some are mild. Some can be very dangerous. And still some can be downright strange.

In news that's bound to disappoint many parents of autistic children, research out of Seattle Children's Hospital and the University of Washington shows that Celexa is no more effective than a placebo in treating repetitive disorders in children with autism spectrum disorders .

Citalopram , a medication commonly prescribed to children with autism spectrum disorders , was no more effective than a placebo at reducing repetitive behaviors, according to a multi-site clinical trial guided by lead author Bryan H. King, MD, director of child and adolescent psychiatry at Seattle Children's Hospital and professor and vice chair of ...

Forest Laboratories a Celexa, part of a class of antidepressants widely prescribed for autistic children, didna t help reduce their repetitive behaviors and caused some of them to have nightmares, a government study found.

U.S. Department of Health and Human Services NATIONAL INSTITUTES OF HEALTH NIH News National Institute of Mental Health Embargoed for Release: Monday, June 1, 2009, 4:00 p.m. EDT CONTACT: Karin Lee, NIMH Press Office, 301-443-4536, Citalopram, a medication commonly prescribed to children with autism spectrum disorders , was no more effective than ...

In contrast to the assumptions of some doctors, new research suggests that the antidepressant Celexa does not help relieve repetitive behaviors often seen in children and teens with autism.

Citalopram, a medication commonly prescribed to children with autism spectrum disorders , was no more effective than a placebo at reducing repetitive behaviors, according to researchers funded by the National Institute of Mental Health and other NIH institutes.

An antidepressant commonly prescribed to help autistic children control their repetitive behaviors is actually no better than a placebo, according to a report published today.

Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that Forest Laboratories' Lexapro is no longer the leading first-line agent of choice for the treatment of major depression.

Earlier this month, the Food and Drug Administration approved Lexapro for the acute and maintenance treatment of major depressive disorder in adolescents 12- to 17-years-old. Here's some basic information about the approval from a Forest Laboratories press release : "The approval of Lexapro for the treatment of adolescent depression was supported ...

Forest Laboratories, maker of the selective serotonin reuptake inhibitor Lexapro , announced on March 20, 2009 that the FDA had approved the drug for the acute and maintenance treatment of major depression in adolescents 12-17 years of age.

I have been on Effexor XR for the last seven years for depression. I decided to wean myself off it, since it wasn't a good mix with another drug.

The FDA is requiring manufacturers of selective serotonin reuptake inhibitors and serotonin-norepinephrine reuptake inhibitors to update their drug warnings with information on neuroleptic malignant syndrome .

Posted by Derek You don't often get to see the sort of fistfight that's detailed in the latest issue of Organic Process Research and Development .